Drug Profile
Lixumistat
Alternative Names: IM-156Latest Information Update: 05 Oct 2023
Price :
$50
*
At a glance
- Originator ImmunoMet Therapeutics
- Class Antifibrotics; Antineoplastics; Biguanides; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Angiogenesis inhibitors; Mitochondrial oxidative phosphorylation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Idiopathic pulmonary fibrosis; Malignant melanoma; Pancreatic cancer
- Preclinical Fibrosis; Gastrointestinal stromal tumours; Prostate cancer
- No development reported Brain cancer; Diffuse large B cell lymphoma; Gastric cancer; Glioblastoma; Lung cancer; Solid tumours
Most Recent Events
- 05 Oct 2023 ImmunoMet Therapeutics plans a phase II trial for Prostate cancer (Hormone refractory) (PO) (ImmuoMet Therapeutics pipeline, July 2023)
- 28 Jul 2023 No recent reports of development identified for preclinical development in Glioblastoma in USA (PO)
- 14 Jul 2023 Phase-I clinical trials in Malignant melanoma in USA (PO) (ImmuoMet Therapeutics pipeline, July 2023)